

SUPPLEMENTARY MATERIAL

Methods

Study data included asthma severity (following GINA guidelines) (1) and control (assessed using the Asthma Control Test) (2). Adherence to treatment was measured with the Test of Adherence to Inhalers (TAI) (3). Table 1 specifies the patient's controller therapy. Table 2 specifies the non-significant comorbidities between both groups. The 2012 Global Lung Initiative reference equations (4) were used to generate predicted values and Z-scores for FEV₁, FVC and FEV₁/FVC ratio.

Table S1. Patient's controller therapy.

	ACT ≥ 20 n = 94	ACT < 20 n = 19	p
Antihistamines, n (%)	43 (46)	9 (47)	0.897
Oral corticosteroids n (%) doses, mg / day	16 (17) 5 (2.5 – 25)	4 (20) 5 (5 – 15)	0.586
LABA, n (%)	87 (92)	19 (100)	0.219
LAMA, n (%)	57 (61)	16 (84)	0.05
Montelukast, n (%)	45 (48)	17 (89)	0.001
Theophylline, n (%)	2 (2)	0 (0)	0.521
Azithromycin, n (%)	9 (9)	7 (37)	0.002

LABA - Long-acting β 2- agonists; LAMA - Long-acting muscarinic antagonists.

Table S2. Control and exacerbations of patients with different biological treatments.

	Omalizumab n = 62	Benralizumab n = 27	Mepolizumab n = 21	Reslizumab n = 3	p
ACT, median (range)	23 (11 – 25)	23 (10 – 25)	25 (16 – 25)	23 (22 – 25)	0.529
ACT < 20, n (%)	11 (18)	4 (15)	2 (9)	0 (0)	
Severe exacerbations, n (%)	18 (29)	4 (15)	4 (19)	0 (0)	0.948
Hospital admissions last 18 months, n (%)	2 (3)	0 (0)	1 (5)	0 (0)	0.417

Table S3. Comorbidities.

	n = 113	ACT ≥ 20 n = 94	ACT < 20 n = 19	p
Atopy, n (%)	81 (72)	66 (79)	15 (79)	0.441
Gastroesophageal reflux, n (%)	21 (19)	15 (16)	6 (31)	0.110
Heart disease, n (%)	6 (5)	5 (5)	1 (5)	0.992
Arterial hypertension, n (%)	27 (24)	20 (21)	7 (37)	0.147
Dyslipidemia, n (%)	27 (24)	23 (24)	4 (21)	0.750
Diabetes, n (%)	8 (7)	7 (7)	1 (5)	0.735
Neurological disease, n (%)	13 (12)	12 (13)	1 (5)	0.350
Psychiatric disease, n (%)	22 (19)	17 (18)	5 (26)	0.409
Digestive disease, n (%)	13 (12)	12 (13)	1 (5)	0.350

References

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. www.ginasthma.org. Accessed September 3, 2020.
2. Vega JM, Badia X, Badiola C, et al. Validation of the Spanish version of the asthma control test (ACT). *J Asthma*. 2007;44:867-872.
3. Plaza V, López-Viña A, Cosío BG. Test of adherence to inhalers. *Arch Bronconeumol*. 2017;53(7):360-361.
4. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012; 40(6):1324–43.